HER2 expression in Brazilian patients with estrogen and progesterone receptor-negative breast carcinoma

dc.creatorRamalho, S
dc.creatorSerra, KP
dc.creatorVassallo, J
dc.creatorSoares, FA
dc.creatorPinto, GA
dc.creatorTeixeira, LC
dc.creatorda Cunha, IW
dc.creatorDerchain, SFM
dc.creatorde Souza, G
dc.date2013
dc.date2014-07-30T17:49:45Z
dc.date2015-11-26T16:33:30Z
dc.date2014-07-30T17:49:45Z
dc.date2015-11-26T16:33:30Z
dc.date.accessioned2018-03-28T23:15:23Z
dc.date.available2018-03-28T23:15:23Z
dc.identifierActa Histochemica. Elsevier Gmbh, Urban & Fischer Verlag, v. 115, n. 2, n. 120, n. 127, 2013.
dc.identifier0065-1281
dc.identifierWOS:000315934400004
dc.identifier10.1016/j.acthis.2012.05.002
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/68267
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/68267
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1270874
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionThe aim of the study was to evaluate the relationship between clinical and pathological factors and survival in patients with double negative HER2-overexpressing carcinoma and triple negative carcinoma. One hundred and sixty-one (161) patients diagnosed with breast cancer negative for estrogen receptor (ER) and progesterone receptor (PR) were included. Of the total, 58 patients had double negative HER2-overexpressing (ER/PR-negative and HER2-positive) and 103 had triple negative (ER-negative, PR-negative and HER2-negative). ER and PR expression was assessed through immunohistochemistry (IHC) and HER2 expression was measured by immunohistochemistry and Fluorescent in situ Hybridization (FISH) analysis in tissue microarray. More than 80% had stages II and III disease and histologic grade III and nuclear grade 3. Patients with triple negative breast carcinoma had undifferentiated histologic types in 11% of cases and vascular invasion in 14.5%. Both groups had more than 50% visceral metastases. HER2 expression (p = 0.42) and vascular invasion (p = 0.05) did not interfere with survival. Survival of patients with Stages I-II disease was significantly longer than in those with Stage III disease both for double negative HER2-overexpressing carcinomas (p < 0.0001) and triple negative carcinomas (p = 0.03). The study shows that hormone receptor-negative breast carcinomas were undifferentiated and diagnosed at advanced stages and that HER2 expression was not associated with overall survival. (C) 2012 Elsevier GmbH. All rights reserved.
dc.description115
dc.description2
dc.description120
dc.description127
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionFAPESP [2009/17097-1]
dc.languageen
dc.publisherElsevier Gmbh, Urban & Fischer Verlag
dc.publisherJena
dc.publisherAlemanha
dc.relationActa Histochemica
dc.relationActa Histochem.
dc.rightsfechado
dc.rightshttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dc.sourceWeb of Science
dc.subjectBreast neoplasms
dc.subjectReceptor
dc.subjectHER2
dc.subjectSurvival analysis
dc.subjectAmerican Society
dc.subjectGuideline Recommendations
dc.subjectClinical Oncology/college
dc.subjectLymphovascular Invasion
dc.subjectMolecular Portraits
dc.subjectCancer
dc.subjectChemotherapy
dc.subjectSurvival
dc.subjectTumors
dc.subjectCyclophosphamide
dc.titleHER2 expression in Brazilian patients with estrogen and progesterone receptor-negative breast carcinoma
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución